Among the analyzed variables, stages III/IV (hazard ratio (HR) 10.93, p = 0.002), distant metastasis (HR 4.68, p = 0.006) and high CLDN6 expression (HR 3.50, p = 0.014) were independent prognostic variables for overall survival of endometrial cancer patients (Table 4). The gene discussed is CLDN6; the disease is endometrial cancer.